(Q37754738)

22 August 2017

Autoantibodies in neuromuscular autoimmune disorders (English)

1 reference

22 August 2017

1 reference

Bethan Lang

1

1 reference

PubMed ID

20477079

22 August 2017

Nick Willcox

series ordinal

2

1 reference

22 August 2017

1 March 2006

1 reference

Expert Review of Clinical Immunology

22 August 2017

1 reference

22 August 2017

2

1 reference

22 August 2017

2

1 reference

22 August 2017

293-307

1 reference

Primary structure of delta subunit precursor of calf muscle acetylcholine receptor deduced from cDNA sequence.

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Refined structure of the nicotinic acetylcholine receptor at 4A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Structure and gating mechanism of the acetylcholine receptor pore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Induction, assembly, maturation and maintenance of a postsynaptic apparatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Sleuthing molecular targets for neurological diseases at the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Distinct phenotypes of congenital acetylcholine receptor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Autoimmune Response to Acetylcholine Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

TREATMENT OF MYASTHENIA GRAVIS WITH PHYSOSTIGMINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Clinical evaluation and management of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Myasthenia gravis: diagnostic and management dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Evidence of underdiagnosis of myasthenia gravis in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

The conformation of the main immunogenic region on the alpha-subunit of muscle acetylcholine receptor is affected by neighboring receptor subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Unravelling the pathogenesis of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Treatment of autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Thymectomy in the management of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Long-term treatment of myasthenia gravis with immunoadsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Immunoadsorption therapy for myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Isolation of potent human Fab fragments against a novel highly immunogenic region on human muscle acetylcholine receptor which protect the receptor from myasthenic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Treatment of refractory autoimmune diseases with ablative immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Novel biological therapies for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Vaccines against myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Response of CD4+ T cells from myasthenic patients and healthy subjects of biosynthetic and synthetic sequences of the nicotinic acetylcholine receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Antigen-specific therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Immune therapy for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

21 January 2018

Anti-adhesion therapies

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Block and tackle: CTLA4Ig takes on lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Prospects for autoimmune disease: Research advances in pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

BP230- and BP180-specific auto-antibodies in bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

21 January 2018

IgG4 breaking the rules

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Potassium channel antibodies in two patients with reversible limbic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

KCNQ2 is a nodal K+ channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Phenotypic variants of autoimmune peripheral nerve hyperexcitability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Peripheral neuropathies and anti-glycolipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Multifocal motor neuropathy human sera block distal motor nerve conduction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Effect of methylprednisolone in patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

Haemolytic Efficiency of Rabbit IgG Anti-Forssman Antibody and its Augmentation by Anti-Rabbit IgG

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.293

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.2.293

1 reference

22 August 2017

1 reference

PubMed ID

20477079